Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities
Metadatos
Mostrar el registro completo del ítemAutor
Zamudio Martínez, Esteban; Herrera-Campos, Ana Belén; Muñoz, Alberto; Rodríguez Vargas, José Manuel; Oliver, Francisco JavierEditorial
Springer Nature
Materia
TNKS1/2 Tankyrase binding motif Proteosomal Degradation
Fecha
2021-04-28Referencia bibliográfica
Zamudio-Martinez E, Herrera-Campos AB, Muñoz A, Rodríguez-Vargas JM, Oliver FJ. (2021). Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities. J Exp Clin Cancer Res. 2021 Apr 28; 40 (1): 144. doi: 10.1186/s13046-021-01950-6
Patrocinador
Agencia Estatal de Investigación SAF2012 (–40011-C02–01, SAF2015–70520-R, RTI2018–098968-BI00, RTICC RD12/0036/0026 and PID2019-104867RB-I00/AEI/https://doi.org/10. 13039/501100011033); Instituto de Salud Carlos III; Fondo Europeo de Desarrollo Regional (CIBERONC ISCIII CB16/12/00421 and CB16/12/00273); Junta de Andalucía, (P10-CTS- 0662, P12-CTS-383); Ministerio de Ciencia e Innovación, Juan de la CiervaResumen
Tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) are two homologous proteins that are gaining increasing importance
due to their implication in multiple pathways and diseases such as cancer. TNKS1/2 interact with a large variety of
substrates through the ankyrin (ANK) domain, which recognizes a sequence present in all the substrates of
tankyrase, called Tankyrase Binding Motif (TBM). One of the main functions of tankyrases is the regulation of protein
stability through the process of PARylation-dependent ubiquitination (PARdU). Nonetheless, there are other
functions less studied that are also essential in order to understand the role of tankyrases in many pathways. In this
review, we concentrate in different tankyrase substrates and we analyze in depth the biological consequences
derived of their interaction with TNKS1/2. We also examine the concept of both canonical and non-canonical TBMs
and finally, we focus on the information about the role of TNKS1/2 in different tumor context, along with the
benefits and limitations of the current TNKS inhibitors targeting the catalytic PARP domain and the novel strategies
to develop inhibitors against the ankyrin domain. Available data indicates the need for further deepening in the
knowledge of tankyrases to elucidate and improve the current view of the role of these PARP family members and
get inhibitors with a better therapeutic and safety profile.





